substance use disorder

The virtual opioid use disorder company reached profitability in Q4 2024, and expanded its team with the appointments of a chief operating officer and chief financial officer.

The funds will be used to increase product offerings, expand the commercial team and move into the substance use disorder space.  

The partnership gives Lantern clients entry into customized substance use disorder treatment and telemedicine services.  

Dr. Yusuf Sherwani, CEO and cofounder of Pelago, describes how the company partners with employers and health plans to control the costs of substance misuse disorders and the effectiveness of the virtual evidence-based treatment platform.